Business
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies
RA Capital Management, LP ("RA Capital"), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today announced that its affiliate alongside an affiliate of OMERS Life Sciences has entered into a senior secured term loan facility of up to $250 million with ARS Pharmaceuticals, Inc. (ARS Pharma), including an initial $100 million investment.
About this update from Ars Pharmaceuticals, Inc.
[{"type":"text","content":"– RA Capital and OMERS Life Sciences provide up to $250 million loan facility to commercial-stage biopharma company ARS Pharma to propel further growth –","length":153,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, Sept. 30, 2025 /PRNewswire/ -- RA Capital Management, LP ("RA Capital"), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today announced that its affiliate alongside an affiliate of OMERS Life Sciences has entered into a senior secured term loan facility of up to $250 million with ARS Pharmaceuticals, Inc. (ARS Pharma), including an initial $100 million investment.","length":489,"tagName":"p"},{"type":"image","alt":"RA Capital Management, LP logo (PRNewsfoto/RA Capital Management, LP)","displaySize":"","headline":null,"caption":"RA Capital Management, LP logo (PRNewsfoto/RA Capital Management, LP)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":86,"url":"https://media.zenfs.com/en/prnewswire.com/0ecf59253f23a2db62ba19595299babf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lbU8_0tTMPbaEENvKLWq.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0ecf59253f23a2db62ba19595299babf","width":400,"height":86},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/qyupRsRK1gY2Q1ykpyVpiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0ecf59253f23a2db62ba19595299babf","width":400,"height":86}},"href":"https://mma.prnewswire.com/media/2374721/RA_Capital_Management_LP_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The financing, which closed on September 29, 2025, illustrates RA Capital's commitment to providing flexible financing solutions across the entire capital stack. ARS Pharma intends to primarily use the financing to support the acceleration of commercial activity for neffy, the company's innovative nasal spray for the emergency treatment of Type 1 allergic reactions including anaphylaxis, an important product that provides a needle-free option for patients and their families.","length":487,"tagName":"p"},{"type":"text","content":""RA Capital has already supported ARS Pharma's development and early commercialization of n...